Porcilis M Hyo

Solid protection against M. hyopneumoniae infections
Both laboratory trials and field trials demonstrate solid protection against M. hyopneumoniae infections when using Porcilis M Hyo.

Rapid onset of immunity and significant protection up until slaughter
Onset of immunity - From 2 weeks after second vaccination.
Duration of immunity -protection proven for at least 20 weeks after second dose.

Porcilis M Hyo protects profits
Significant reduction in pulmonary lesions due to M. hyopneumoniae infection and consistently improved weight gain during the fattening period is seen even on farms with a low M. hyopneumoniae challenge.

No interference by MDA
Trial data indicate that the efficacy of Porcilis M Hyo is not affected by the presence of maternal antibodies at the time of vaccination:

  • All field trials involving the vaccination of MDA+ pigs resulted in a significant reduction in lung lesions and a consistently improved weight gain during the fattening period.
  • Results of vaccination/challenge studies were the same irresepective of the presence of MDA.
  • There is no correlation between MDA levels at vaccination and the efficacy of Porcilis M Hyo.

More information:

Merck Animal Health also has M+PAC® and Myco Silencer® Once available for the prevention of M. hyo infections.

M+PAC® offers the choice of a single dose or double dose vaccination program.

Myco Silencer® ONCE was specifically developed and designed as a single dose Mycoplasma hyopneumoniae bacterin.

The three vaccines give customers flexibility in their choice of M. hyo control.

Combining Porcilis PRRS and Porcilis M Hyo

Porcilis PRRS and Porcilis M Hyo can be mixed and administered to pigs from 4 weeks of age. The combination is for the control of Porcine Reproductive and Respiratory Syndrome (PRRS) and protection against M. hyopneumoniae infections in finishing pigs.

For more information see Porcilis PRRS + Porcilis M Hyo.

Porcilis M Hyo

Trial data indicate that the efficacy of Porcilis M Hyo is not affected by the presence of maternal antibodies at the time of vaccination.